Maxim Group analyst Anthony Vendetti maintained a Buy rating on Venus Concept (VERO – Research Report) yesterday and set a price target of $1.75. The company’s shares closed yesterday at $0.41.
Vendetti covers the Healthcare sector, focusing on stocks such as Pulse Biosciences, ReShape Lifesciences, and Venus Concept. According to TipRanks, Vendetti has an average return of -2.6% and a 32.10% success rate on recommended stocks.
Currently, the analyst consensus on Venus Concept is a Moderate Buy with an average price target of $1.88, implying a 361.80% upside from current levels. In a report released on October 3, BTIG also reiterated a Buy rating on the stock with a $2.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $2.43 and a one-year low of $0.29. Currently, Venus Concept has an average volume of 580.2K.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VERO in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Venus Concept, Inc. is a medical aesthetic technology company. Its product portfolio consists of aesthetic device platforms which includes venus versa, venus legacy, venus velocity, venus fiore, venus viva, venus freeze plus, and venus bliss. The company was founded in 2002 and is headquartered in Toronto, Canada.
Read More on VERO:
- What You Missed On Wall Street On Monday
- What You Missed On Wall Street This Morning
- Venus Concept Announces Appointment of Rajiv De Silva as Chief Executive Officer and Director; Updates Fiscal Year 2022 Revenue Guidance
- Venus Concept sees Q3 revenue of at least $21M, consensus $24.53M
- Venus Concept withdraws 2022 revenue guidance
